Abstract
The article discusses the application and effectiveness of drug Aflazin® manufactured by Valartin Pharma Ltd. as an antimicrobial therapy in pregnant women with diabetes mellitus in the II-III trimesters with uncomplicated urinary tract infection.In the course of the study, 91 women aged 18–40 years were examined. Patients were randomized into 2 groups: 45 women entered group I (main), and group II (comparisons) – 46 pregnant women. All women received basic antibiotic therapy used in the clinic for the treatment of chronic nonspecific urinary tract infections. Additionally, pregnant women from the comparison group received Aflazin® 1 capsule 2 times a day for 15 days.Characteristics of the clinical course of the disease in pregnant women of both groups were homogeneous. The main signs of uncomplicated urinary tract infection were frequent painful urination in small portions, pain in the lower abdomen and in the lumbar region, an increase in body temperature. In 80% of cases, when studying the bacterial culture of the urine of pregnant women, microorganisms were detected in various associations.After using the drug Aflazin®, changes in the immunological reactivity of the organism were revealed due to a decrease in the level of CD4+-helpers and an increase in the percentage of phagocytosis. There was a change in the microbial spectrum of the organism towards the disappearance of the pathological flora in the urine. In the course of the study, a positive dynamics of the subjective and objective state of the examined women was obtained, a good tolerability and safety of the drug was noted.Complex therapy, supplemented with Aflazin®, had a significant positive effect on the overall condition of pregnant women. Efficacy of treatment as sufficient or high was noted in 45 (97.8%) cases from 46 in the comparison group and in 20 (44.4%) cases from 45 in the main group. The results obtained make it possible to recommend Aflazin® for the complex treatment of nonspecific urinary tract infections in women with diabetes mellitus in the II and III trimesters of pregnancy.
Highlights
The article discusses the application and effectiveness of drug Aflazin® manufactured by Valartin Pharma Ltd. as an antimicrobial therapy
The results obtained make it possible to recommend Aflazin® for the complex treatment of nonspecific urinary tract infections in women with diabetes mellitus in the II and III trimesters of pregnancy
Summary
КРИВУЩЕНКО аспирант отделения акушерской эндокринологии и врожденных пороков развития плода ГУ «ИПАГ НАМН Украины», врач акушер-гинеколог ORCID: 0000-0002-9323-381X. Беременность у женщин, больных СД, вызывает анатомо-функциональные нарушения в мочевой системе и иммунитете, что способствует возникновению гестационного или обострению хронического пиелонефрита, частота которого, по данным разных авторов, составляет от 5 до 30% [3,11,13]. АНАЛИЗ ЛИТЕРАТУРНЫХ ДАННЫХ И ПОСТАНОВКА ЗАДАЧИ ИССЛЕДОВАНИЯ Терминология, классификация, факторы риска 1) Инфекция мочевыделительных путей (ИМП) – наиболее частое осложнение беременности при СД 3) Среди неосложненных ИМП у беременных с СД в 40% случаев наблюдается бессимп томная бактериурия, когда при наличии размножения бактерий в моче отсутствуют какие-либо клинические проявления. 5) Пиелонефрит – неспецифическое инфекционно-воспалительное заболевание почек (одно- или двустороннее), при котором в патологический процесс вовлекаются почечная лоханка, чашки и паренхима почек (в первую очередь, интерстиций и канальцевый аппарат), а также клубочки и почечные сосуды.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
